Performance data surfaced, not buried in a spec sheet.
Diagnostics site design puts sensitivity and specificity figures directly on the page, because that is what a clinical buyer wants before anything else and a download only slows that down.
A clinical buyer wants sensitivity and specificity figures immediately — the architecture puts that data directly on the page rather than requiring a download to find the number that actually drives the decision.
Overstating what a test detects is a regulatory risk here in a way it is not for most other pharmaceutical categories, so precision in wording matters more than usual. Getting the design right starts from that fact, not from a moodboard.
An architecture that surfaces performance data directly on the page, a component system built around sensitivity and specificity figures, and a review of what currently requires a download to find.
A clinical buyer wants sensitivity and specificity data before anything else — the architecture surfaces that data directly rather than making a visitor dig through a technical PDF to find the number that actually drives the decision.
Diagnostics companies usually organise a website around platforms and product families, which reflects how the business is structured rather than how a laboratory evaluates. The unit that matters to a laboratory director is the individual assay: its sample type, analytical performance, platform compatibility, throughput and regulatory status in their market. When assays only exist as rows in a downloadable menu, they cannot be linked to, compared or found. Giving each one a real page — generated from your product data rather than hand-built — is usually the single change that makes the largest difference to how the site performs commercially.
An assay may be CE marked under the in vitro diagnostic regulation, cleared in one market, available for research use only in another and not offered at all in a third. Presenting a single global status is at best unhelpful and at worst a compliance problem, particularly for research-use-only products, where the boundary against clinical claims is closely watched. Holding status per market as structured data, and rendering the correct statement to each visitor, makes the position explicit everywhere and removes the recurring editorial risk of a page that was accurate when it was written and is not any more.
What comes up when scoping a site for this category.
Typically a clinical or laboratory buyer checking sensitivity and specificity data before anything else, arriving with intent close to “diagnostic test sensitivity specificity” rather than a general product query. This reader is evaluating whether a test performs well enough for their own patient population, so validation data needs to be reachable within the first few clicks, not treated as supporting material further down the page.
Validation data should sit as structured, sourced figures next to the test itself, not summarized loosely in marketing copy. Sensitivity, specificity, sample size, and the population studied all need to be visible together, since a clinical buyer will otherwise assume the data is being softened. Linking through to the underlying study or regulatory filing gives that buyer a way to verify the claim independently.
Yes — that includes structured validation-data pages, clinician-facing resource libraries, and workflows for requesting samples or kits directly from a test page. See Diagnostics for the full range of platforms and content we build for this sector, most of it built around how a clinical buyer evaluates a test before adopting it.
Where your operations support it, yes — a request workflow can sit directly on the test page rather than routing through a separate contact form. That keeps the request close to the validation data the clinician just reviewed, shortens the path from evaluation to trial, and gives your team a qualified lead already tied to a specific test and patient population.
By holding regulatory status as a per-market attribute of the assay rather than as a sentence in the page copy, and rendering the applicable statement and disclaimer based on the visitor’s market. That keeps the research-use-only boundary intact where it applies without hiding the product from markets where it is cleared. Doing it in the content model rather than by maintaining separate country sites also means a status change is one field to update rather than a search across every page that mentions the assay.
A design that photographs well and still loses a clinical buyer checking sensitivity and specificity data halfway through the page. Tell us what you have tried and we will tell you what we think is actually going on. Tell us your situation and we will tell you what a rebuild for a clinical buyer checking sensitivity and specificity data would actually change.